The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Specific Mutations in the β-Catenin Gene (CTNNB1) Correlate with Local Recurrence in Sporadic Desmoid Tumors
Open accessAbstract
Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Molecular determinants of desmoid recurrence remain obscure. beta-Catenin deregulation has been commonly identified in sporadic desmoids although the incidence of CTNNB1 (the gene encoding beta-catenin) mutations is uncertain. Consequently, we evaluated the prevalence of CTNNB1 mutations in a large cohort of sporadic desmoids and examined whether mutation type was relevant to desmoid outcome. Desmoid specimens (195 tumors from 160 patients, 1985 to 2005) and control dermal scars were assembled into a clinical data-linked tissue microarray. CTNNB1 genotyping was performed on a 138-sporadic desmoid subset. Immunohistochemical scoring was performed per standard criteria and data were analyzed using Kaplan-Meier and other indicated methods. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: 41A (59%), 45F (33%), and 45P (8%, excluded from further analysis because of rarity). Five-year recurrence-free survival was significantly poorer in 45F-mutated desmoids (23%, P < 0.0001) versus either 41A (57%) or nonmutated tumors (65%). Nuclear beta-catenin expression was observed in 98% of specimens and intensity was inversely correlated with incidence of desmoid recurrence (P < 0.01). In conclusion, CTNNB1 mutations are highly common in desmoid tumors. Furthermore, patients harboring CTNNB1 (45F) mutations are at particular risk for recurrence and therefore may especially benefit from adjuvant therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt/β-Catenin Signaling in Development and Disease
Clevers, H. (2006) · Cell · doi:10.1016/j.cell.2006.10.018 · Cited by 5,568
Identification of FAP Locus Genes from Chromosome 5q21
Kinzler, K. W., Nilbert, M. C., Su, L.-K., Vogelstein, B., Bryan, T. M., Levy, D. B., Smith, K. J., Preisinger, A. C., Hedge, P., McKechnie, D., et al. (1991) · Science · doi:10.1126/science.1651562 · Cited by 2,355
The many ways of Wnt in cancer
Polakis, P. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.007 · Cited by 866
β-catenin: a key mediator of Wnt signaling
Willert, K., & Nusse, R. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80068-3 · Cited by 753
The oncogenic activation of β-catenin
Polakis, P. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80003-3 · Cited by 653
The Desmoid Tumor. I.: Incidence, Sex-, Age- and Anatomical Distribution in the Finnish Population
Reitamo, J. J., Häyry, P., Nykyri, E., & Saxen, E. (1982) · American Journal of Clinical Pathology · doi:10.1093/ajcp/77.6.665 · Cited by 597
Wnt signaling: is the party in the nucleus?
Willert, K., & Jones, K. A. (2006) · Genes & Development · doi:10.1101/gad.1424006 · Cited by 589
Ballo, M. T., Zagars, G. K., Pollack, A., Pisters, P. W. T., & Pollock, R. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.158 · Cited by 501
Self-citationKoch, A., Denkhaus, D., Albrecht, S., Leuschner, I., von Schweinitz, D., & Pietsch, T. (1999) · PubMed · Cited by 399
Gronchi, A., Casali, P. G., Mariani, L., Lo Vullo, S., Colecchia, M., Lozza, L., Bertulli, R., Fiore, M., Olmi, P., Santinami, M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.150 · Cited by 354
Cited by
Kasper, B., Baumgarten, C., Garcia, J., Bonvalot, S., Haas, R., Haller, F., Hohenberger, P., Penel, N., Messiou, C., van der Graaf, W. T., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx323 · Cited by 422
Self-citationGeyer, F. C., Lacroix-Triki, M., Savage, K., Arnedos, M., Lambros, M. B., MacKay, A., Natrajan, R., & Reis-Filho, J. S. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.205 · Cited by 373
A Prognostic Nomogram for Prediction of Recurrence in Desmoid Fibromatosis
Crago, A. M., Denton, B., Salas, S., Dufresne, A., Mezhir, J. J., Hameed, M., Gonen, M., Singer, S., & Brennan, M. F. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31828c8a30 · Cited by 278
A Pan-cancer Transcriptome Analysis Reveals Pervasive Regulation through Alternative Promoters
Demircioğlu, D., Cukuroglu, E., Kindermans, M., Nandi, T., Calabrese, C., Fonseca, N. A., Kahles, A., Lehmann, K.-V., Stegle, O., Brazma, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.018 · Cited by 250
Kummar, S., O'Sullivan Coyne, G., Do, K. T., Turkbey, B., Meltzer, P. S., Polley, E., Choyke, P. L., Meehan, R., Vilimas, R., Horneffer, Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.1994 · Cited by 183
Complex reconstruction of desmoid tumor resections does not increase desmoid tumor recurrence.
Garvey, P. B., Booth, J. H., Baumann, D. P., Calhoun, K. A., Liu, J., Pollock, R. E., & Butler, C. E. (2013) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2013.04.038 · Cited by 19
Self-citationCavallini, A., Rotelli, M. T., Lippolis, C., Piscitelli, D., Digennaro, R., Covelli, C., Carella, N., Accetturo, M., & Altomare, D. F. (2017) · Oncotarget · doi:10.18632/oncotarget.16383 · Cited by 17
Metadata
- Authors
- Lazar, A. J. F., Tuvin, D., Hajibashi, S., Habeeb, S., Bolshakov, S., Mayordomo-Aranda, E., Warneke, C. L., Lopez-Terrada, D., Pollock, R. E., & Lev, D.
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2008-11
- Volume
- 173
- Issue
- 5
- Pages
- 1518-1527
- ISSN
- 0002-9440 (ISSN-L)
- OpenAlex
- W2116318030
- Cited by
- 455
- References
- 33
- FWCI
- 13.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
